INSYS rises on FDA OK of fentanyl breakthrough cancer pain spray
This article was originally published in Scrip
Executive Summary
Shares of INSYS Therapeutics climbed as high as 36.4% on 5 January after the US FDA approved Subsys fentanyl sublingual spray as a treatment for breakthrough cancer pain in adults already receiving and tolerant to opioid therapy for their underlying persistent cancer pain.